Low-dose, continuous enzyme replacement therapy ameliorates brain pathology in the neurodegenerative lysosomal disorder mucopolysaccharidosis type IIIA

Journal of Neurochemistry

Volumn 137, Issue 3, 2016, Pages 409-422

  King, Barbara ^a   Hassiotis, Sofia ^a   Rozaklis, Tina ^a   Beard, Helen ^a   Trim, Paul J ^a   Snel, Marten F ^a   Hopwood, John J ^a   Hemsley, Kim M ^a  

^a SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

heparan sulphate; inflammation; lysosomal; mouse; mucopolysaccharidosis; osmotic pump

Indexed keywords

BIOLOGICAL MARKER; CHONDROITIN SULFATE; DRUG ANTIBODY; GANGLIOSIDE GM3; HEPARAN SULFATE; NEUROINFLAMMATORY MARKER; RECOMBINANT ENZYME; RECOMBINANT HUMAN SULFAMIDASE; UNCLASSIFIED DRUG; HYDROLASE; N-SULFOGLUCOSAMINE SULFOHYDROLASE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CERVICAL SPINAL CORD; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG STABILITY; ENZYME ACTIVITY; ENZYME REPLACEMENT; GLIOSIS; HUMAN; IMMUNOHISTOCHEMISTRY; IMPLANTATION; LATERAL BRAIN VENTRICLE; LOW DRUG DOSE; MALE; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SANFILIPPO SYNDROME; TANDEM MASS SPECTROMETRY; VENTRICULAR CANNULA (BRAIN); ANIMAL; BRAIN; BRAIN CHEMISTRY; C57BL MOUSE; IMPLANTABLE INFUSION PUMP; METABOLISM; MUCOPOLYSACCHARIDOSIS III; PATHOLOGY; PROCEDURES; SPINAL CORD;

ANIMALS; BIOMARKERS; BRAIN; BRAIN CHEMISTRY; ENZYME REPLACEMENT THERAPY; GLIOSIS; HEPARITIN SULFATE; HUMANS; HYDROLASES; INFUSION PUMPS, IMPLANTABLE; LATERAL VENTRICLES; MICE; MICE, INBRED C57BL; MUCOPOLYSACCHARIDOSIS III; RECOMBINANT PROTEINS; SPINAL CORD;

EID: 84956641344     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13533     Document Type: Article

References (36)

1. Beard H., Hassiotis S., Luck A. J., Rozaklis T., Hopwood J. J., and, Hemsley K. M., (2015) Continual low-dose infusion of sulfamidase is superior in ameliorating neuropathology in the MPS IIIA mouse brain to intermittent high-dose delivery. JIMD Rep. DOI: 10.1007/8904-2015-495.
2. Bentley J. N., Viswanathan A., Rosenberg W. S., and, Patil P. G., (2014) Treatment of medically refractory cancer pain with a combination of intrathecal neuromodulation and neurosurgical ablation: case series and literature review. Pain Med. 15, 1488-1495.
3. Bhaumik M., Muller V. J., Rozaklis T., et al,. (1999) A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome). Glycobiology 9, 1389-1396.
4. Bobyk L., Edouard M., Deman P., Rousseau J., Adam J. F., Ravanat J. L., Estève F., Balosso J., Barth R. F., and, Elleaume H., (2012) Intracerebral delivery of carboplatin in combination with either 6 MV photons or monoenergetic synchrotron X-rays are equally efficacious for treatment of the F98 rat glioma. J. Exp. Clin. Cancer Res. 31, 78.
5. Bolash R., Udeh B., Saweris Y., Guirguis M., Dalton J. E., Makarova N., and, Mekhail N., (2015) Longevity and cost of implantable intrathecal drug delivery systems for chronic pain management: a retrospective analysis of 365 patients. Neuromodulation 18, 150-155.
6. Camargo F., Erickson R. P., Garver W. S., Hossain G. S., Carbone P. N., Heidenreich R. A., and, Blanchard J., (2001) Cyclodextrins in the treatment of a mouse model of Niemann-Pick C disease. Life Sci. 70, 131-142.
7. Chang M., Cooper J. D., Sleat D. E., Cheng S. H., Dodge J. C., Passini M. A., Lobel P., and, Davidson B. L., (2008) Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol. Ther. 16, 649-656.
8. Crawley A. C., Gliddon B. L., Auclair D., Brodie S. L., Hirte C., King B. M., Fuller M., Hemsley K. M., and, Hopwood J. J., (2006) Characterisation of a C57BL/6 congenic mouse strain of mucopolysaccharidosis type IIIA. Brain Res. 1104, 1-17.
9. Crawley A. C., Marshall N., Beard H., et al,. (2011) Enzyme replacement reduces neuropathology in MPS IIIA dogs. Neurobiol. Dis. 43, 422-434.
10. Dodge J. C., Clarke J., Treleaven C. M., et al,. (2009) Intracerebroventricular infusion of acid sphingomyelinase corrects CNS manifestations in a mouse model of Niemann-Pick A disease. Exp. Neurol. 215, 349-357.
11. Gliddon B. L., and, Hopwood J. J., (2004) Enzyme-replacement therapy from birth delays the development of behavior and learning problems in mucopolysaccharidosis type IIIA mice. Pediatr. Res. 56, 65-72.
12. Heldermon C. D., Hennig A. K., Ohlemiller K. K., Ogilvie J. M., Herzog E. D., Breidenbach A., Vogler C., Wozniak D. F., and, Sands M. S., (2007) Development of sensory, motor and behavioral deficits in the murine model of Sanfilippo syndrome type B. PLoS ONE 2, e772.
13. Hemsley K. M., King B., and, Hopwood J. J., (2007) Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice. Mol. Genet. Metab. 90, 313-328.
14. Hemsley K. M., Beard H., King B. M., and, Hopwood J. J., (2008) Effect of high dose, repeated intra-CSF injection of sulphamidase on neuropathology in MPS IIIA mice. Genes Brain Behav. 7, 740-753.
15. Hemsley K. M., Norman E. J., Crawley A. C., Auclair D., King B., Fuller M., Lang D. L., Dean C. J., Jolly R. D., and, Hopwood J. J., (2009a) Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs-a proof of principle study. Mol. Genet. Metab. 98, 383-392.
16. Hemsley K. M., Luck A. J., Crawley A. C., Hassiotis S., Beard H., King B., Rozek T., Rozaklis T., Fuller M., and, Hopwood J. J., (2009b) Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease. Eur. J. Neurosci. 29, 1197-1214.
17. Hopwood J. J., and, Elliott H., (1982) Diagnosis of Sanfilippo type A syndrome by estimation of sulfamidase activity using a radiolabelled tetrasaccharide substrate. Clin. Chim. Acta 123, 241-250.
18. Jolly R. D., Allan F. J., Collett M. G., Rozaklis T., Muller V. J., and, Hopwood J. J., (2000) Mucopolysaccharidosis IIIA (Sanfilippo syndrome) in a New Zealand Huntaway dog with ataxia. N. Z. Vet. J. 48, 144-148.
19. Jolly R. D., Marshall N. R., Perrott M. R., Dittmer K. E., Hemsley K. M., and, Beard H., (2011) Intracisternal enzyme replacement therapy in lysosomal storage diseases: routes of absorption into brain. Neuropathol. Appl. Neurobiol. 37, 414-422.
20. Karpova E. A., Voznyi Y. V., Keulemans J. L., Hoogeveen A. T., Winchester B., Tsvetkova I. V., and, van Diggelen O. P., (1996) A fluorimetric enzyme assay for the diagnosis of Sanfilippo disease type A (MPS IIIA). J. Inherit. Metab. Dis. 19, 278-285.
21. Lau A. A., Hannouche H., Rozaklis T., Hassiotis S., Hopwood J. J., and, Hemsley K. M., (2010) Allogeneic stem cell transplantation does not improve neurological deficits in mucopolysaccharidosis type IIIA mice. Exp. Neurol. 225, 445-454.
22. Li H. H., Zhao H.-Z., Neufeld E. F., Cai Y., and, Gomez-Pinilla F., (2002) Attenuated plasticity in neurons and astrocytes in the mouse model of Sanfilippo syndrome type B. J. Neurosci. Res. 69, 30-38.
23. Margetis K., Korfias S., Boutos N., et al,. (2014) Intrathecal baclofen therapy for the symptomatic treatment of hereditary spastic paraplegia. Clin. Neurol. Neurosurg. 123, 142-145.
24. Martínez J. A., Pinsker M. O., Arango G. J., Garcia X., Oscar A. E., Furlanetti L., Reithmeier T., Aranda I. A., Marin J. H., and, Lopez W. O., (2014) Neurosurgical treatment for dystonia: long-term outcome in a case series of 80 patients. Clin. Neurol. Neurosurg. 123, 191-198.
25. Miyake J. A., Benadiba M., Ribeiro G., DE Oliveira Silva D., and, Colquhoun A., (2014) Novel ruthenium-gamma-linolenic acid complex inhibits C6 rat glioma cell proliferation in vitro and in the orthotopic C6 model in vivo after osmotic pump infusion. Anticancer Res. 34, 1901-1911.
26. Paxinos G., and, Franklin K. B. J., (2001) The mouse brain in Stereotaxic Co-ordinates. Academic Press, USA.
27. Rozaklis T., Beard H., Hassioitis S., Garcia A. R., Tonini M., Luck A., Pan J., Lamsa J. C., Hopwood J. J., and, Hemsley K. M., (2011) Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA. Exp. Neurol. 230, 123-130.
28. Savas P., Hemsley K. M., and, Hopwood J. J., (2004) Intracerebral injection of sulfamidase delays neuropathology in murine MPS-IIIA. Mol. Genet. Metab. 82, 273-285.
29. Scott H. S., Blanch L., Guo X. H., Freeman C., Orsborn A., Baker E., Sutherland G. R., Morris C. P., and, Hopwood J. J., (1995) Cloning of the sulphamidase gene and identification of mutations in Sanfilippo A syndrome. Nat. Genet. 11, 465-467.
30. Sohn Y. B., Lee J., Cho S. Y., Kim S. J., Ko A. R., Nam M. H., and, Jin D. K., (2013) Improvement of CNS defects via continuous intrathecal enzyme replacement by osmotic pump in mucopolysaccharidosis type II mice. Am. J. Med. Genet. A 161A, 1036-1043.
31. Stetkarova I., Brabec K., Vasko P., and, Mencl L., (2015) Intrathecal baclofen in spinal spasticity: frequency and severity of withdrawal syndrome. Pain Physician 18, E633-E641.
32. Stroobants S., Gerlach D., Matthes F., Hartmann D., Fogh J., Gieselmann V., D'Hooge R., and, Matzner U., (2011) Intracerebroventricular enzyme infusion corrects central nervous system pathology and dysfunction in a mouse model of metachromatic leukodystrophy. Hum. Mol. Genet. 20, 2760-2769.
33. Trim P. J., Lau A. A., Hopwood J. J., and, Snel M. F., (2014) A simple method for early age phenotype confirmation using toe tissue from a mouse model of MPS IIIA. Rapid Commun. Mass Spectrom. 28, 933-938.
34. Valstar M. J., Ruijter G. J., van Diggelen O. P., Poorthuis B. J., and, Wijburg F. A., (2008) Sanfilippo syndrome: a mini-review. J. Inherit. Metab. Dis. 31, 240-252.
35. Vitry S., Aussiel J., Hocquemiller M., Bigou S., dos Santos Coura R., and, Heard J. M., (2009) Enhanced degradation of synaptophysin by the proteasome in mucopolysaccharidosis type IIIB. Mol. Cell Neurosci. 41, 8-18.
36. Wilkinson F. L., Holley R. J., Langford-Smith K. J., et al,. (2012) Neuropathology in mouse models of Mucopolysaccharidosis type I, IIIA and IIIB. PLoS ONE 7, e35787.